

Supplement table 1. Baseline characteristics of relapse and resistant groups

Patients Characteristic	Relapse cases	Resistant cases	p value
	(n = 21)	(n = 38)	
Female, n (%)	21 (100)	37 (97.4)	0.45
Age at enrollment (years; mean \pm SD)	34.3 \pm 9.1	31.6 \pm 11.0	0.35
Systolic blood pressure (mmHg; ; mean \pm SD)	132 \pm 13	132 \pm 21	0.98
Diastolic blood pressure (mmHg; ; mean \pm SD)	86 \pm 14	85 \pm 16	0.96
Serum creatinine (mg/dL; mean \pm SD)	1.09 \pm 0.50	0.86 \pm 0.34	0.046
eGFR by CKD-EPI (ml/min/1.73m ² ; mean \pm SD)	80.8 \pm 35.8	96.8 \pm 26.3	0.05
Range of eGFR (ml/min / 1.73 m ² ; n [%])			
\geq 90 ml/min/1.73 m ²	10 (47.6)	26 (68.4)	
60-89 ml/min/1.73 m ²	3 (14.3)	7 (18.4)	
45-59 ml/min/1.73 m ²	2 (9.5)	4 (10.5)	
30-44 ml/min/1.73 m ²	5 (23.8)	0 (0.0)	
25-30 ml/min/1.73 m ²	1 (4.8)	1 (2.6)	
Hemoglobin (g/dL; mean \pm SD)	10.6 \pm 1.5	11.0 \pm 1.8	0.50
Hematocrit (%; mean \pm SD)	32.8 \pm 4.8	33.3 \pm 5.2	0.72
Serum albumin (g/dL; mean \pm SD)	2.63 \pm 0.64	2.86 \pm 0.73	0.26
Serum complement (mg/dL, mean \pm SD)			
C3 concentration	52.7 \pm 22.4	82.6 \pm 34.2	0.001
C4 concentration	11.6 \pm 6.3	20.5 \pm 13.7	0.016
UPCR (mean \pm SD)	7.3 \pm 5.7	8.7 \pm 5.7	0.36
Nephrotic range proteinuria (\geq 3.5 g/day), n (%)	15 (71.4)	31 (81.6)	0.37
Urine red blood cell (cells/hpf; mean \pm SD)	25.5 \pm 66.6	29.2 \pm 52.5	0.82

Urine white blood cell (cells/hpf; mean+/- SD)	13.6 ± 32.1	14.4 ± 51.6	0.95
--	-------------	-------------	------

Note: eGFR; estimated glomerular filtration rate, CKD-EPI; Chronic Kidney Disease

Epidemiology Collaboration, C3; Complement component 3, C4; Complement component 4,

UPCR; urine protein creatinine ratio (mg/mg), SD; standard deviation

Supplement table 2. Primary outcomes of treatment focusing on the relapse cases (n=21)

Variables	CYC (N=11)		EC-MPS (N=10)		percentage difference between groups†		P Value
	no.	%	no.	%	%	(95% CI)	
Complete remission							
At 6 th month	4/9	44.44	1/10	10.00	34.44	(-2.9 to 71.9)	0.07
At 12 th month	4/9	44.44	2/10	20.00	24.44	(-16.4 to 65.3)	0.24
Partial remission							
At 6 th month	3/9	33.33	4/10	40.00	-6.67	(-49.9 to 36.6)	0.76
At 12 th month	3/9	33.33	5/10	50.00	-16.67	(-60.4 to 27.0)	0.46
Non-remission							
At 6 th month	2/9	22.22	5/10	50.00	-27.78	(-69.0 to 13.4)	0.19
At 12 th month	2/9	22.22	3/10	30.00	-7.78	(-47.1 to 31.5)	0.70
Discontinuation &							
0-6 th month	2/11	18.18	0/10	0.00	18.18	(-4.6 to 41.0)	0.12
7-12 th month	0/9	0.00	0/10	0.00	0.00	(-0.0 to 0.0)	1.00
0-12 th month	2/11	18.18	0/10	0.00	18.18	(-4.6 to 41.0)	0.12
Composite outcome §							
0-6 th month	4/11	36.36	5/10	50.00	-13.64	(-55.7 to 28.4)	0.53
7-12 th month	2/9	22.22	3/10	30.00	-7.78	(-47.1 to 31.5)	0.70
0-12 th month	4/11	36.36	3/10	30.00	6.36	(-33.8 to 46.5)	0.76

Supplement table 3. Primary outcomes of treatment focusing on the resistant cases (n=38)

Variables	CYC (N=21)		EC-MPS (N=17)		percentage difference between groups†		P Value
	no.	%	no.	%	%	(95% CI)	
Complete remission							
At 6 th month	3/16	18.75	2/15	13.33	5.42	(-20.3 to 31.1)	0.68
At 12 th month	5/16	31.25	5/14	35.71	-4.46	(-38.3 to 29.4)	0.80
Partial remission							
At 6 th month	5/16	31.25	8/15	53.33	-22.08	(-56.0 to 11.9)	0.20
At 12 th month	5/16	31.25	5/14	35.71	-4.46	(-38.3 to 29.4)	0.80
Non-remission							
At 6 th month	8/16	50.00	5/15	33.33	16.67	(-17.5 to 50.9)	0.34
At 12 th month	6/16	37.50	4/14	28.57	8.93	(-24.6 to 42.4)	0.60
Discontinuation ^{&}							
0-6 th month	5/21	23.81	2/17	11.76	12.04	(-11.8 to 35.8)	0.32
7-12 th month	0/16	0.00	1/15	6.67	-6.67	(-19.3 to 6.0)	0.30
0-12 th month	5/21	23.81	3/17	17.65	6.16	(-19.5 to 31.9)	0.64
Composite outcome [§]							
0-6 th month	13/21	61.90	7/17	41.18	20.73	(-10.6 to 52.0)	0.19
7-12 th month	6/16	37.50	5/15	33.33	4.17	(-29.5 to 37.8)	0.81
0-12 th month	11/21	52.38	7/17	41.18	11.20	(-20.5 to 42.9)	0.49

Note: CYC; cyclophosphamide, EC-MPS; Enteric-coated Mycophenolate Sodium, CI; confidence interval

† The difference is shown as the value for group1 minus the value for group 2

[&] Including either death, major infection, doubling of serum creatinine and loss of follow-up

[§] Including either death, doubling of serum creatinine, non-remission or intolerance to treatment